Exclusive Online Content
Lantheus Grants Rights for the Use of its Microbubbles to SonoThera for its Ultrasound-Guided Nonviral Gene Therapy Platform
Lantheus Holdings, Inc. recently announced a strategic collaboration with SonoThera, Inc. in which Lantheus’ microbubbles will be used in combination with SonoThera’s ultrasound-guided, nonviral, gene…
UM171 Cell Therapy Demonstrates Improved Outcomes Compared to Cord & Matched Unrelated Donor Peripheral Blood Transplants in Real-World Setting
ExCellThera Inc. recently announced findings from a safety and efficacy retrospective analysis comparing outcomes of patients treated with ECT-001 (UM171-expanded) Cell Therapy in a Phase 1/2 trial to those treated with….
Catalent Opens One of the World’s Largest Commercial-Scale Cell Therapy Manufacturing Facilities at its European Center of Excellence for Cell Therapies in Belgium
Catalent recently announced the completion and opening of a new commercial-scale cell therapy manufacturing facility at its European center of excellence for cell therapies in….
Metrion Biosciences & The KCNC1 Foundation Collaborate on Development of New Ion Channel Modulators for Ultra-Rare Genetic Disorder
Metrion Biosciences Limited and The KCNC1 Foundation recently announced a collaboration to progress a hit identification research project for small molecule modulators of the….
Summit Therapeutics Partners With Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody
Summit Therapeutics Inc. recently announced a definitive agreement of its partnership with Akeso Inc. to in-license its breakthrough bispecific antibody, ivonescimab…..
Incannex Expands Intellectual Property Position Over IHL-42X
Incannex Healthcare Limited recently announced the filing of a provisional patent application directed to the use of IHL-42X for the treatment of Obstructive Sleep Apnoea….
Enzyvant Announces Merger With Altavant
Combined company has full range of capabilities required to advance bold science for rare diseases in immunology and cardiopulmonology….
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS
ATH-1105 demonstrated consistent improvements across measures of motor function, nerve function, and neurodegeneration in a TDP-43 mouse model of ALS….
Wheeler Bio Licenses ATUM’s Proprietary Leap-In Transposase Technology in Support of its Disruptive CDMO Service Offering
Wheeler Bio, Inc. recently announced it has been granted a license to ATUM’s proprietary Leap-In Transposase and miCHO cell line development technology…..
Roivant & Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory & Fibrotic Diseases
Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal antibody that blocks tumor necrosis factor-like ligand 1A (TL1A), a cytokine believed to play a key role in inflammation and fibrosis ….
Ryvu Therapeutics & BioNTech Enter Global Collaboration to Develop & Commercialize Immuno-Modulatory Small Molecule Candidates
The companies enter a multi-target research collaboration to develop multiple small molecule programs targeting immune modulation in cancer and potentially other disease areas based on targets selected by BioNTech….
First Wave BioPharma Files INDA for Enhanced Microgranule Delivery Formulation of Adrulipase
Upon IND clearance, Phase 2 clinical trial investigating adrulipase as a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis is expected to initiate in early 2023 with topline clinical data anticipated in the first half of 2023….
Avectas, CCRM & OmniaBio Expand Their Collaboration to Accelerate the Manufacture of Edited iPSCs Using SOLUPORE Technology
Avectas and CCRM, with its subsidiary OmniaBio Inc., have recently announced an expansion of their collaboration, to enable the development of gene-edited induced pluripotent stem….
Immutep Enters Second Clinical Trial Collaboration Agreement With Merck KGaA & Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha & Avelumab to Treat Urothelial Cancer
New collaboration builds on encouraging clinical data previously reported from INSIGHT-004 in multiple solid tumor indications from the combination of eftilagimod alpha (efti) and avelumab (BAVENCIO)….
Incannex Engages Eurofins to Manufacture Novel Addiction Treatments CannQuit-N and CannQuit-O
Incannex Healthcare Limited recently announced it has engaged multinational contract development and manufacturing organisation (CDMO) Eurofins Scientific to manufacture Incannex’s two distinct medicated….
uniQure Announces FDA Approval of First Gene Therapy for Adults With Hemophilia B
Historic approval provides a new treatment option that reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy, and generates elevated and sustained factor IX levels….
XOMA Acquires Royalty & Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon
XOMA assumes the rights to ebopiprant from ObsEva, including the Organon License, Patent Estate, and Merck KGaA, Darmstadt, Germany, license, for a $15 million outlay….
RxCelerate Acquires Methuselah Health & Launches ProQuant World-Beating Proteomics Service
Next-generation proteomics technology made available to the biotech and pharmaceutical industry through the acquisition of Methuselah Health by leading R&D services provider, RxCelerate….
Evaxion Announces Promising Results From Phase 1/2a Clinical Trial of Personalized DNA Cancer Immunotherapy
Evaxion Biotech A/S recently announced promising clinical data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02….
Attralus & Ossianix Announce Option & License Agreement Using the TXP1 Brain Shuttle for Targeted Delivery of a Pan-Amyloid Removal Therapeutic for Neurodegenerative Disorders
Attralus, Inc. and Ossianix recently announced they have entered into a definitive agreement using Ossianix’ brain shuttle technology to enhance the targeted delivery of novel….
